Life Science

Ellex Raidla advises a wide range of companies in the life sciences sector, including the fields of pharmaceuticals, medical devices, biotech, nanotech and other based on medical law. We help build and protect healthcare and life sciences companies through our extensive background in regulatory, intellectual property, licensing, litigation, product liability, unfair competition, trade secret, antitrust, merger and acquisition, tax and other matters. Our medical malpractice lawyers assisted the State Agency of Medicine in compiling field-specific regulations and participated in drafting of various acts of related legislation.
Key projects in the field

Key contacts

Ants Nõmper

Managing Partner

Head of Intellectual Property & IT practice group
+ 372 640 7170

Key projects in the field

We are advising BaltCap Private Equity Fund II on the acquisition of Kaarli Hambapolikliinik OÜ
BaltCap through its holding company DenCap Investments acquires one of the leading
Estonian dental care providers Kaarli Hambapolikliinik OÜ. This is the largest deal in the dental care sector in Estonia.

BaltCap is the leading dedicated private equity and venture capital investor in the Baltic states (Estonia, Latvia and Lithuania ).  BaltCap has a long experience in the medical sector and  is strongly established in the field. The company is or has previously been the owner of several well-known companies in the Estonian medical sector: occupational health care company Qvalitas, the largest medical laboratory services provider SYNLAB (ex Quattromed) and clinical research organization eGeen. BaltCap also owns Unimed Group and their dental clinics in Tallinn, Tartu and Pärnu, as well as a dental laboratory Dental Design. In Lithuania BaltCap is the owner of the InMedica chain of primary care and specialized clinics, and Labochema, which offers laboratory supplies in the Baltics.

Kaarli Dental Lab was established in 1999 in Tallinn, Estonia. It is one of the biggest dental laboratories in Estonia with dental clinics in three locations in Tallinn, where they provide dental care using modern techniques and treatment methods. In 2017 Kaarli Dental Lab’s total turnover was 9.4 MEUR.

The deal is advised by Partner Ermo Kosk, Counsel Toomas Kasesalu, Senior Associates Sandra Värk, Dmitri Rozenblat, Associates Marilin Laud, Kerstin Jürgenson and Merlin Liis.
Advised Cellin Technologies OÜ regarding unique cell medicine project
Ellex Raidla partner Ants Nõmper advised Cellin Technologies OÜ in preparation of the documents regarding the unique cell medicine project. Cellin Technologies OÜ is the first company that started producing  personalized cancer medicine called MelCancerVac.

The personal cell medicine that is in the final phase of test point, is based on amplifying patient's body defensive reaction, using the patient's blood-derived dendritic cells and the melanoma cell lysate. If the trials are successful, MelCancerVac may become the world’s first vaccine against colorectal cancer.

Cellin Technologies OÜ is a cell therapy products contract manufacturing company founded in 2008 that is using modern cleanroom facility for the production of cell therapy medicinal products of the highest quality. The company is participating in the EU- funded Research and Development project, which studies how to the use of regenerative cells from human fat in the creation of new blood vessels.

Additional information:
Advising Medicine Estonia Cluster regarding the standard contracts
Ellex Raidla partner Ants Nõmper advised Medicine Estonia Cluster regarding the preparation of standard contracts for provision of health care services, including contracts regarding the patients’ approval and the preparation of anaesthesia leaflets in Estonian, Russian, English and Finnish.

Medicine Estonia is a project of Service Industry Association supporting its members in increasing their export of medical services. One of the main roles of the cluster is to market the services of its members in target markets and to create an attractive image for the Estonian service providers.

Additonal information: